Summary
The investigational drug romosozumab produced significantly greater improvements in volumetric bone mineral density (vBMD) and volumetric bone mineral content (vBMC) compared with both placebo and teriparatide in postmenopausal women with low bone mass in a substudy of an international multicenter randomized Phase 2 trial.
- Metabolic Bone Disease Bone Density & Structure Disorders Clinical Trials
- Metabolic Bone Disease
- Metabolic Bone Disease
- Rheumatology
- Bone Density & Structure Disorders
- Rheumatology Clinical Trials
- © 2014 MD Conference Express®
Tools
Romosozumab Bone Benefits at 1 Year versus Teriparatide in Postmenopausal Women
Permalink:
Table of contents
Cited By...
- No citing articles found.